Target intelligence / Profile preview

AP-4 complex subunit epsilon-1 (AP4E1)

Target
AP4E1
Molecular classification
Adaptor protein, Vesicle coat component, Heterotetrameric adaptor protein complex subunit
01

Overview

AP-4 complex subunit epsilon-1 (AP4E1) is a critical component of the heterotetrameric adaptor protein complex 4 (AP-4), which mediates the sorting and transport of transmembrane cargo from the trans-Golgi network to the endosomal-lysosomal system (UniProt, PubMed: 10066790). It plays a vital role in neuronal homeostasis by ensuring the proper localization of proteins such as ATG9A, which is essential for autophagosome biogenesis and autophagic flux (Ma'ayan Lab, PubMed: 26542808). Loss-of-function mutations in the AP4E1 gene are the primary cause of Hereditary Spastic Paraplegia type 51 (SPG51), a neurodevelopmental disorder characterized by progressive spasticity, intellectual disability, and microcephaly (GeneCards, OMIM: 607244). Additionally, heterozygous variants in AP4E1 have been associated with familial persistent stuttering (PubMed: 26542808). While there are currently no approved small-molecule drugs targeting AP4E1, it is a significant focus for gene replacement therapies aimed at restoring AP-4 complex function in affected patients (Open Targets). Research also suggests a potential link between AP-4 deficiency and broader neurodegenerative processes, including Alzheimer's disease (Ma'ayan Lab).

Other names
Adaptor related protein complex 4 subunit epsilon 1AP-4 adaptor complex subunit epsilonAdaptor-related protein complex 4 subunit epsilon-1Epsilon subunit of AP-4Epsilon-adaptinSPG51CPSQ4STUT1
02

Mechanism of action

None currently approved; gene replacement therapy is under investigation to restore protein function and AP-4 complex assembly in deficiency syndromes.

03

Biological functions

Vesicle-mediated transportProtein sortingIntracellular protein transportAutophagy regulationCargo selectionNeuronal homeostasis
04

Disease associations

Hereditary Spastic Paraplegia 51 (SPG51)Neurodegenerative diseaseIntellectual disabilityFamilial persistent stutteringCerebral palsyMicrocephaly
05

Safety considerations

Potential for off-target effects in gene therapyImmune response to viral vectorsDisruption of autophagic pathways if overexpressedNeurodevelopmental toxicity
06

Biomarkers

AP4E1 gene mutationsATG9A mislocalizationReduced autophagic fluxThin corpus callosum (imaging biomarker)Lower limb spasticity

Beyond the preview

Go deeper on AP-4 complex subunit epsilon-1 (AP4E1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on AP-4 complex subunit epsilon-1 (AP4E1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call